Podcasts about Cart

Y'a t'il une norme en matière d'amour ? Y'a t'il un moule dans lequel on doit se fondre, un modèle à suivre, un idéal à atteindre ? Si vous êtes fidèles à ce podcast vous savez bien que non. Alors quand il s'agit de différence d'âge, pourquoi porte-t-on ce regard critique ? Pourquoi ces «elle cherche son père» «il a besoin d'une mère» «il prend une jeunette parce qu'il ne veut pas vieillir» ? Caroline y a bien pensé à toutes ses phrases.. mais quand l'amour est là, vous le savez maintenant, plus aucun cliché ne compte, évidemment.[REDIFF]

LikeFolio's Andy Swan is bullish on DoorDash (DASH), citing strong consumer demand that continues to outpace Uber Technologies (UBER) and Maplebear's (CART) Instacart. He says investments in AI, automation, and delivery tech position the company for long-term growth despite short-term profit concerns.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

A leading New Zealand research institute believes it is on track to deliver a cutting edge immunotherapy for blood cancer patients in the public system next year. But only if it can get government funding. Researchers at the Malaghan Institute are well into clinical trials of CAR-T cell therapy with 60 patients. The institute's Clinical Director, Doctor Robert Weinkove spoke to Lisa Owen.

Link Up w/The Morning Sickness Digitally All Over:Instagram: @hms_98_official, @bosskupd, @bretvesely, @dickToledoX/Twitter: @HMSon98, @DickToledo, @bretveselyFacebook: @HMSKUPDYouTube: @hmspodcast9320, @98kupdRequest/Call in/Wakeup Song line:(IN AZ) 602.585.9800More HMS: holmbergpodcast.com, 98kupd.comEmail: dtoledo@98kupd.com, bvesely@98kupd.com, bbogen@98kupd.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Link Up w/The Morning Sickness Digitally All Over:Instagram: @hms_98_official, @bosskupd, @bretvesely, @dickToledoX/Twitter: @HMSon98, @DickToledo, @bretveselyFacebook: @HMSKUPDYouTube: @hmspodcast9320, @98kupdRequest/Call in/Wakeup Song line:(IN AZ) 602.585.9800More HMS: holmbergpodcast.com, 98kupd.comEmail: dtoledo@98kupd.com, bvesely@98kupd.com, bbogen@98kupd.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Rare disease research is creating new paths for diagnosis, treatment, and broader medical discovery. Gene therapy can repair or replace faulty genes, and work on cystinosis has led to a stem cell platform now being applied to Danon disease, Sanfilippo syndrome C, Friedreich's ataxia, and Alzheimer's research. Funding programs support gene therapy, clinical trials, and new platform approaches for rare diseases. CAR-T cell research is also advancing treatment possibilities for pediatric brain tumors, including early results in children with DIPG and diffuse midline glioma. A patient advocate shares her daughter's diagnostic odyssey and treatment for TUBB4A leukodystrophy. Together, these stories show why rare disease research matters beyond rarity. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41402]

Rare disease research is creating new paths for diagnosis, treatment, and broader medical discovery. Gene therapy can repair or replace faulty genes, and work on cystinosis has led to a stem cell platform now being applied to Danon disease, Sanfilippo syndrome C, Friedreich's ataxia, and Alzheimer's research. Funding programs support gene therapy, clinical trials, and new platform approaches for rare diseases. CAR-T cell research is also advancing treatment possibilities for pediatric brain tumors, including early results in children with DIPG and diffuse midline glioma. A patient advocate shares her daughter's diagnostic odyssey and treatment for TUBB4A leukodystrophy. Together, these stories show why rare disease research matters beyond rarity. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41402]

Trump annule in extremis les frappes contre l'Iran et évoque un accord imminent les marchés y croient, le pétrole s'effondre sous 90 dollars, l'Iran dément. Pendant ce temps, la BCE réalise sa première hausse de taux depuis 2023 en portant son taux de dépôt à 2,25%, piégée par une inflation zone euro à 3,2% alimentée directement par le choc Hormuz. SpaceX entre en bourse aujourd'hui sur le Nasdaq sous le ticker SPCX à une valorisation de 1 750 milliards de dollars la plus grande IPO de l'histoire. Et aux États-Unis, le CPI de mai confirme 4,2% d'inflation annuelle : le pivot tant attendu s'éloigne encore, des deux côtés de l'Atlantique.

Poolbeg Pharma PLC (AIM:POLB) principal scientist Liam Tremble joined Proactive's Stephen Gunnion to discuss the first site activation for Poolbeg's POLB 001 TOPICAL clinical trial, evaluating the drug as a preventative treatment for cytokine release syndrome (CRS), a serious side effect linked to CAR-T and bispecific antibody therapies. The UK study will enrol 30 multiple myeloma patients receiving teclistamab, with early readouts expected due to CRS typically occurring within the first two weeks of treatment. Tremble also highlighted new data presented at the EHA Congress showing POLB 001 reduced inflammatory cytokines without compromising tumour-killing activity, alongside early research suggesting potential applications in acute myeloid leukaemia (AMS). For more interviews and market insights, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications so you never miss future content. #PoolbegPharma #POLB001 #Biotech #MultipleMyeloma #AML #AcuteMyeloidLeukemia #CancerResearch #Immunotherapy #CRS #CytokineReleaseSyndrome #Teclistamab #BloodCancer #ClinicalTrials #EHA2026 #HealthcareInnovation

Full show notes: https://bengreenfieldlife.com/dralbert In this episode, Dr. Pradeep Albert breaks down the science behind HarmonIQ, formerly Hapbee, a wearable wellness company using frequency-based technology to help you access specific physiological states on demand, from deeper sleep and sharper focus to stress reduction and addiction support, all without ingesting anything. This episode also marks the official launch of HarmonIQ and its new pet-focused line Hapbee Pets. You'll discover why quality sleep without pills is the non-negotiable foundation on which every advanced longevity therapy sits, what Dezawa MuseCells are doing to cartilage and bone in professional athletes who would otherwise be facing surgery, and where CAR T-cell therapy is headed over the next decade. You'll also gain insights into peptide stacks including LL-37, ipamorelin, tessamorelin, MOTS-c, PT-141, cerebrolysin, and GHK-Cu, and what the recent FDA reclassification of 14 peptides back to Category 1 means for anyone currently using or considering them. Dr. Pradeep Albert, MD, DABR, is a board-certified musculoskeletal radiologist, author, and internationally recognized thought leader in regenerative medicine and longevity science. Over three decades, he has performed thousands of regenerative procedures, treated professional athletes across the NFL, MLB, NBA, and NHL, published over 50 peer-reviewed articles, and shaped peptide and stem cell legislation across multiple countries including advising heads of state on healthcare policy. He is the CEO of Vesalius Longevity Labs, founder of the American Academy of Peptide Medicine, and creator of RadSherpa, an AI-powered diagnostic platform now deployed in 89 countries. Save $50 on your HarmonIQ Limitless Neckband and Hapbee Pets Pad (discount auto-applied). Episode Sponsors Fatty15: Fatty15 is on a mission to optimize your C15:0 levels and help you live healthier, longer. You can get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/BEN and using code BEN at checkout. Hiya: Give your kids the full-body nourishment they need to grow into healthy adults. I’ve secured a special deal with Hiya on their best-selling children's vitamin—get 50% off your first order today! To claim this deal, you must go to hiyahealth.com/BEN (it is not available on their regular website). Young Goose: To experience the transformative power of Young Goose's cutting-edge skincare products, visit younggoose.com and use code BGF10 at checkout to enjoy a 10% discount on your order. Quantum Upgrade: Recent research has revealed that the Quantum Upgrade was able to increase ATP production by a jaw-dropping 20–25% in human cells. Unlock a 15-day free trial with the code BEN15 at quantumupgrade.io. Pendulum: Metabolic Daily is a powerful multi-strain probiotic that improves your metabolism, reduces sugar cravings, breaks down carbs more efficiently, and sustains your energy levels. You’ll receive 20% off your first month of any Pendulum probiotic with code BEN at PendulumLife.com.See omnystudio.com/listener for privacy information.

Dr. Shuvro Roy and Dr. Amanda Piquet discuss a brief overview of stiff person syndrome, as well as the trial and the trial results.  Read more about this abstract on the AAN website.   Show transcript:  Dr. Shuvro Roy: Hi, this is Shuvro Roy from the University of Washington and welcome to today's Neurology Minute. I just wrapped a longer conversation with Amanda Piquet from the University of Colorado Anschutz School of Medicine. We were just talking about the recent Phase 2 trial evaluating Miv-cel Kyverna Therapeutics' anti-CD19 CAR T-cell therapy in patients with Stiff Person Syndrome. Amanda, would you mind taking us through a brief overview of SPS as well as the trial and their trial results? Dr. Amanda Piquet: So Stiff Person Syndrome, or SPS, is a rare disabling autoimmune neurologic disease with a major unmet need. About 80% of patients ultimately lose their mobility and we currently have no FDA approved therapies. Existing treatments like IVIG, rituximab, and plasmapheresis are all used off label, often requiring chronic dosing and frequently failing to stop progression. KYSA-8 is a registrational Phase 2 study of 26 patients with refractory SPS. Patients experienced rapid, statistically significant and clinically meaningful improvement across all primary and secondary endpoints. Primary endpoint was the timed 25-foot walk. And this improved by a median of 46% at 16 weeks. Of patients requiring walking aids at baseline, about two thirds no longer needed them by week 16 to complete that 25-foot walk. Some patients who had struggled to walk were even able to run again after treatment. Another key finding was that all patients discontinued chronic immune therapies and remained off treatment as of the last follow-up. From a safety standpoint, miv-cel was generally well tolerated, with no high grade CRS or ICANS observed. In my opinion, these outcomes are unlike anything we've seen previously with Stiff Person Syndrome and may represent a paradigm shift, not only for SPS, but potentially for other antibody-mediated neurologic diseases more broadly. Dr. Shuvro Roy: Just curious, are there any upcoming implications for the application of this treatment for patients, you think, in the coming year or so? Dr. Amanda Piquet: Kyverna, the company who developed miv-cel, has initiated a rolling BLA with the FDA for potential approval and this would be, if approved, the first CAR-T therapy for SPS. So we're anxiously awaiting the outcome of that process. Dr. Shuvro Roy: Fantastic. Amanda, thank you so much for your time. And if you are intrigued and want to know more details behind the findings in the study as well as a conversation around CAR-T therapy for autoimmune neurologic disease as a whole, I encourage you to check out the Neurology Podcast feed for our full conversation there. Thanks for tuning in.  

Dr. Shuvro Roy and Dr. Amanda Piquet discuss a brief overview of stiff person syndrome, as well as the trial and the trial results.  Read more about this abstract on the AAN website.   Show transcript:  Dr. Shuvro Roy: Hi, this is Shuvro Roy from the University of Washington and welcome to today's Neurology Minute. I just wrapped a longer conversation with Amanda Piquet from the University of Colorado Anschutz School of Medicine. We were just talking about the recent Phase 2 trial evaluating Miv-cel Kyverna Therapeutics' anti-CD19 CAR T-cell therapy in patients with Stiff Person Syndrome. Amanda, would you mind taking us through a brief overview of SPS as well as the trial and their trial results? Dr. Amanda Piquet: So Stiff Person Syndrome, or SPS, is a rare disabling autoimmune neurologic disease with a major unmet need. About 80% of patients ultimately lose their mobility and we currently have no FDA approved therapies. Existing treatments like IVIG, rituximab, and plasmapheresis are all used off label, often requiring chronic dosing and frequently failing to stop progression. KYSA-8 is a registrational Phase 2 study of 26 patients with refractory SPS. Patients experienced rapid, statistically significant and clinically meaningful improvement across all primary and secondary endpoints. Primary endpoint was the timed 25-foot walk. And this improved by a median of 46% at 16 weeks. Of patients requiring walking aids at baseline, about two thirds no longer needed them by week 16 to complete that 25-foot walk. Some patients who had struggled to walk were even able to run again after treatment. Another key finding was that all patients discontinued chronic immune therapies and remained off treatment as of the last follow-up. From a safety standpoint, miv-cel was generally well tolerated, with no high grade CRS or ICANS observed. In my opinion, these outcomes are unlike anything we've seen previously with Stiff Person Syndrome and may represent a paradigm shift, not only for SPS, but potentially for other antibody-mediated neurologic diseases more broadly. Dr. Shuvro Roy: Just curious, are there any upcoming implications for the application of this treatment for patients, you think, in the coming year or so? Dr. Amanda Piquet: Kyverna, the company who developed miv-cel, has initiated a rolling BLA with the FDA for potential approval and this would be, if approved, the first CAR-T therapy for SPS. So we're anxiously awaiting the outcome of that process. Dr. Shuvro Roy: Fantastic. Amanda, thank you so much for your time. And if you are intrigued and want to know more details behind the findings in the study as well as a conversation around CAR-T therapy for autoimmune neurologic disease as a whole, I encourage you to check out the Neurology Podcast feed for our full conversation there. Thanks for tuning in.  

“I wanna hear THAT at my grocery store, when I'm going for the meat section…”   Whether it's the song we all rise for at sports ball events,  the first song on Rush's “Fly By Night” album (not to mention the first song on Anthrax's EP of classic rock covers), or the sing-along, encore at the end of a rock show, ANTHEMS represent a clarion call, a rallying cry that unites fans in unspeakable joy, unity, and celebration. It's almost always the song that EVERYONE knows (even your grandmother) and is very much NOT a deep cut.    “AC/DC's kind of an anthem band…they have at least one on every album…”   In fact, ANTHEMS are those kinds of songs where, if you hear one in a public place: at a bar, a restaurant, the grocery store, or a friend's party, you're not going to NOT like it. Sure, it's probably the most well-known, popular, played into the ground, mainstream “hit” that EVERYONE (again, probably even your grandmother) is familiar with, but no matter what song it is or where you might hear it, ANTHEMS are  guaranteed to get you fired up, lift your spirit, and bring a smile to your face.   “I wanna do a little birthday squig…”   Find out what's happening “THIS FRIDAY”, realize that birthdays are the anniversaries of life, and JOIN US for a Bunkerpoon birthday celebration full of cake, refreshments, and good cheer as we cuss and discuss the unifying power behind rock and metal ANTHEMS. Visit www.metalnerdery.com/podcast for more on this episode Help Support Metal Nerdery https://www.patreon.com/metalnerderypodcast Leave us a Voicemail to be played on a future episode: 980-666-8182 Metal Nerdery Tees and Hoodies – metalnerdery.com/merch and kindly leave us a review and/or rating on your favorite Podcast app Follow us on the Socials: Facebook - Instagram - TikTok Email: metalnerdery@gmail.com Can't be LOUD Enough Playlist on Spotify Metal Nerdery Munchies on YouTube @metalnerderypodcast   Show Notes: (00:01): “I think I just turned it up…”/ “I'm upright and taking nourishment…”/  “I'll give myself the bean…”/ “I'll put it wherever you want…you want it on the inside or the outside?” / ***WARNING: #listenerdiscretionisadvised *** / #keepitthrashy / “Maybe he just unlocked another dimension with his weed…”/ “Dr. Pepper, Captain Morgan, and PB&J's…”/ #yeah / #McDonalds #DirtyDrPepper #Rim / “Was the rim the best part?” / “If you have foam down there, you should really go see your doctor…to have him finish you to completion…”/ ***WELCOME BACK TO THE METAL NERDERY PODCAST AND THE BUNKERPOON CENTER FOR METAL EXCELLENCE!!!*** / #happybirthday / #birthdayepisode / “I eat once a day…I'm the lightest I've been in 3 years…”/ “A handful of food, 5 times a day…”/ #cavemandiet / “Fasting is the way…”/ “Now they're saying that sugar is WORSE than heroin…”/ “It's all mental…” (07:37): ***PATREON US at patreon.com/metalnerderypodcast *** / #SpiritInTheSky /  “I was looking at the name: I thought it said ‘My Boss'…”/ ***SOCIAL MEDIA US at #MetalNerderyPodcast on #YouTube #Facebook #InstaGram and #TikTok *** / #drysockets and #wisdomteeth #viralaf / #Pyscroptic GATHERING A VENOMOUS HERD / (The Pulse of Annihilation – 2026) / #technicaldeathmetal / #Tasmania #Australia #AussieMetal / “They got a Wiki page, that's saying something…”/ Tasmania, Australia (“Yeah…”) / “How any albums do they have?” / “Let's go through the album titles…”/  “You wanna watch a video?”/ #youwatchamovie / ARCHITECTS OF EXTINCTION /  “Those guys are re-tah-diculous!” / The reaction of laughter to unbelievable riffs and technical prowess   (18:18): “So here's what we've got to contend with…I'm gonna ask you, right here in front of everybody…” / “You think God listens to this podcast, dude?”/ “I wanna do a little birthday squig in the beginning…”/ “This year marks the 25th anniversary of Pig Destroyer's Prowler In The Yard, which is like the Reign In Blood of grindcore…”/ “I've got a kink now, where I can't get off unless Stephen Hawking is watching…”/ “I hate this so bad…”/ “This is beautiful…this is art.” /  #PigDestroyer JENNIFER/CHEERLEADER CORPSES (Prowler In The Yard – 2001) /  #TwentyFifthAnniversary #ProwlerInTheYard / “Oh, I farted…”/ “A little bit of WHAT?” / PISS ANGEL / “Is that better or worse?”/ “Should we start calling birthdays anniversaries instead of birthdays?”   (24:00): #TheDocket METAL NERDERY PODCAST PRESENTS: ANTHEMS / “It's gotta be bolth…” / #rockanthems #heavymetalanthems / “What is an anthem? What do you think of when you hear the word ‘anthem' (if it's metal or rock)?”/ “Everybody knows it…it gets people fired up…”/ “When the band plays the song where you all become a part of the show…that's the sing along…”/ “What is the first anthem you can think of?” /  “Everybody knows it…it's the one that your grandmother has heard…it's the non-deep cut…”/ “What would Van Halen's anthem be?”/ #BetterOffDead /  “What would AC/DC's anthem be?”/ “AC/DC's kind of an anthem band…they have at least one on every album…”/ “Did we just unlock a new dimension here?” (30:06): “What's a Zeppelin anthem?” / “We're all humans, who cares?”/ #markthetime /  “Anthems are one of those things…if you hear it at a public place like in a bar, a restaurant, or even at the grocery store…”/ “Cart…buggy…”/ “You can't NOT like it…even if you're a #Rush super deep cut fan…”/ #BlackSabbath WAR PIGS (Paranoid – 1970) /  “Now we're smiling, all of a sudden…”/ “I don't know if you've ever heard this before…about that song…those first few words…it almost has a country vibe to it…the vocal…”/  “They put the Eventide voice machines on him…”/ “All the guitar nerds will get that…”/  “What's an Eventide? Is that like a dildo or something? What do you do with that?”/  “What about Ozzy anthems?”   (38:48): #Motorhead ACE OF SPADES (Ace Of Spades – 1980) / “This is one of the most metal parts, evah!”/ “If your doctor doesn't recommend metal to you as a lifestyle improvement and a medical treatment, find a different doctor.”/ “Was the Van Hagar more anthem-y than the Roth era?” / “Yeah…you've got to, with the hairdryer and the whole thing…you don't remember the video?” / #hairdryerASMR / “Soooo…for metal bands…”/  #IronMaiden THE NUMBER OF THE BEAST (The Number Of The Beast – 1982) / “Everybody in America is like: ‘You went to the pub and got pissed off? What's wrong with you?' / “I've got one…”/ #QuietRiot METAL HEALTH (Metal Health – 1983) / “Assgrinder?”/ “That's a sing-along…”/ “Which do you think was bigger?” / “I think that's what possibly killed Twisted Sister…”/ #TwistedSister I WANNA ROCK (Stay Hungry – 1984) / #No / “How much fun was that?” / “Every band probably has their own anthem…”/ “Testament, what would be theirs?” / “For the mainstream customer…but for their fans, it would be…”/  “It is a weird anthem…that's probably one of their encores…” (51:55): “Everybody knows the Pantera one…”/ “At a bar, at a party, at a friend's house…if I hear it in a public place…I'm not complaining…I'm cool with that.”/ “It still feels like it belongs to you…”/ “Do you feel like they (Metallica) are almost in the AC/DC bucket?” / “Does your grandmother know Dyer's Eve?” / “What's Creed's anthem?”/  #Pantera COWBOYS FROM HELL (Cowboys From Hell – 1990) / “I wanna hear THAT at my grocery store, when I'm going for the meat section…”/ #markthetime / “Fun and anthems kinda go together…”/ “I don't NOT like ‘Walk'…” (58:58): “I got another one for us metal heads…”/ #StormtroopersOfDeath MARCH OF THE S.O.D. (Speak English Or Die – 1985) / “Does #Anthrax have an anthem?” / “Okay, so how about Priest?” / #abigone / “Let me know if you think this is THEIR anthem…it's gotta be…”/  “THIS FRIDAY!” / #keepitin / “That was awesome…”/ #KoRn BLIND (KoRn – 1994) / “That's gotta be, right?” / “Are you ready!?” / “This Friday…are you ready?”  (1:04:00): “What is the most recent rock or metal anthem you can think of?” /  “Has everybody lost their ability to do anthems?”/ “The anthem is the call to arms…”/  “Here's my answer to that question…in my opinion…”/ “See, I thought that was Cake…” / #TheWhiteStripes SEVEN NATION ARMY (Elephant – 2003) / “I'll take the bottom off?” /  “What's the band that everybody fucks with…everybody hates on them…?”/ “Nickelback has some anthems, for sure…now that you mention it, maybe not…”/ “That's how I clap, by the way…”/ THANK YOU FOR JOINING US!!! / #untilthenext #outroreel

In this week's episode, Blood editor Dr. Philippe Armand interviews Drs. Manali Kamdar and Nancy L. Bartlett on their latest review article published in Blood titled “From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma”. They discuss the how the advent of chimeric antigen receptor T cells, antibody-drug conjugates, and bispecific antibodies all show major increases in efficacy over legacy chemotherapy-based regimens. They also share their insights on how to transform treatment paradigms in light of these breakthroughs.

In this episode, Bernie and Anthony are joined by Myeloma Man Manni Mohyuddin, MD to discuss the debate surrounding the treatment of first relapse in multiple myeloma. Should we be using CAR-T? Bispecifics? How does the new mezigdomide data from ASCO 2026 inform our practice? Listen in for a spicy discussion!Articles discussed:Nature Reviews Commentary: https://www.nature.com/articles/s41571-026-01159-6CARTITUDE-4: https://www.nature.com/articles/s41571-026-01159-6MajesTEC-3: https://www.nejm.org/doi/full/10.1056/NEJMoa2514663 MajesTEC-9: https://www.nejm.org/doi/abs/10.1056/NEJMoa2603870 Control arms in multiple myeloma trials: https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2026020329/567836/Improving-Control-Arms-in-2026-U-S-Myeloma-TrialsPredictors for CAR T cell therapy-associated immune-related adverse events? https://pubmed.ncbi.nlm.nih.gov/41540109/Dex prophylaxis for lymphocytosis: https://ashpublications.org/bloodadvances/article/10/10/3629/567462/Dexamethasone-prophylaxis-for-excessive-lymphocyteMezi-KD vs. KD ASCO 2026: https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA7506

Two recent studies have shown remarkable advances in HIV cure research: (1) a Norwegian man who achieved long-term HIV remission after a stem cell transplant from his brother and (2) a Phase 1 trial testing CAR-T cell therapy. On this episode, Antonio Urbina, MD, Medical Director for CEI's HIV Primary Care and Prevention Center of Excellence, dives into these studies and puts them into clinical context, including how to discuss cure research with patients. Related Content: CEI Line: 1-866-637-2342  https://ceitraining.org/ Clinicaltrials.gov

Join Drs. Jack Cush, Alfred Kim, Janet Pope, and Yuz Yusof for a focused conversation on the latest in CAR-T from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping CAR-T practice right now.

Krissy Dilger of SRNA welcomed University of Washington neuroimmunologist Dr. Shuvro Roy for an open Q&A on transverse myelitis (TM). Dr. Roy explained how TM can be both a presentation and a diagnosis, with “idiopathic TM” used when extensive testing finds no underlying cause and noted that recurrence should prompt reevaluation for conditions like NMOSD, MOGAD, or neurosarcoidosis and consideration of preventive immunotherapy [00:06:16]. He addressed audience questions about lifestyle and rehabilitation topics including diet, metabolic health, exercise, sleep issues, and safe considerations around CBD or THC-containing gummies, and reviewed approaches to chronic pain, spasticity, physical therapy timelines, and spinal cord stimulation (including ArcX) [00:13:20]. Dr. Roy also discussed the current status of peptides and stem cells, highlighted emerging cell-based therapies like CAR-T, and answered a case question about a high MOG antibody titer and its diagnostic implications [00:24:53].Shuvro Roy, MD is an Assistant Professor of Neurology at the University of Washington, specializing in neuroimmunology, with a specific focus on multiple sclerosis (MS) and related neuroimmunologic disorders. He is Co-Director of the UW SRNA Center of Excellence for Rare Neuroimmune disorders. He is also a core teaching faculty member for the UW Medicine Multiple Sclerosis Center's fellowship program, contributing to clinical education and research initiatives like the ECHO MS program in collaboration with the National MS Society. Dr. Roy is actively engaged in projects aimed at improving access to care, addressing healthcare disparities, and enhancing patient safety for individuals living with MS and related conditions. He has co-authored recent research articles in medical journals on a variety of topics, including studies on stiff person syndrome, encephalomyelitis, MOG-antibody disorder, and multiple sclerosis treatment protocols. Dr. Roy is dedicated to helping his patients thrive amid challenging, lifelong neurological conditions.00:00:00 Welcome and Introductions00:01:24 What Is Transverse Myelitis00:03:30 Common Causes and Mechanisms00:06:16 Diagnosis Versus Presentation00:10:39 Monophasic or Recurrent00:13:20 Diet Do's and Don'ts00:17:25 Aging and Long-Term Health00:24:53 Peptides and Stem Cells00:33:07 Fatigue Sleep and CBD or THC-containing gummies00:37:58 Chronic Pain Options00:43:55 Physical Therapy Recovery00:47:56 Spinal Cord Stimulation ArcX00:51:46 Stopping Pregabalin Safely00:52:59 Trials and Rehab at Any Age00:56:00 MOG Titer and Diagnosis01:00:02 Closing

A New Zealand blood cancer patient who was forced to leave his children behind and make a last chance dash to Australia to access funded drugs has now been given a cutting edge transplant that is not publicly available here. Tawhai Reti, who has myeloma, had exhausted all treatment options in NZ. Earlier this year he moved to Australia without his family to access the lifesaving drug Daratumamab, which isn't funded here. It worked so well he has now been given CAR-T cell therapy, which could put him into remission indefinitely. Tawhai and Lani Reti spoke to Lisa Owen.

Organização Internacional do Trabalho, OIT, afirma que 138 milhões de crianças trabalham no mundo; diretor-geral da entidade diz que avanços demonstram que é possível erradicar o trabalho infantil, mas que ele ainda está longe do fim; Dia Mundial de Combate ao Trabalho Infantil é marcado neste 12 de junho.

summaryDr. Debbie Ozment explores how ultra-processed foods and additives like emulsifiers impact gut health, emphasizing the importance of discerning ingredient labels to promote vitality and overall well-being.keywordsgut health, ultra-processed foods, emulsifiers, CMC, polysorbate 80, gut microbiome, health tips, food labels, vitality, inflammationkey topicsImpact of ultra-processed foods on gut healthRole of emulsifiers like CMC and P80 in gut inflammationHow to read food labels for better health choicesDisclaimer: This podcast is for general information and entertainment purposes only and does not constitute medical or dental advice. Any mention of products, services, tests, or supplements is not an endorsement and may include affiliate links. Guest views are their own and may not reflect the views of Dr. Debbie Ozment or this podcast. Always consult a qualified healthcare professional for advice specific to your situation.Visit my website DrDebbieOzment.com for valuable free downloads.  Additionally,  you will find shopping links which I have curated on the website.  Please follow me on instagram at drdebbieozment.

What actually happens at a major international medical conference — and why should patients care? In this episode of The Health Advocates, Steven Newmark reports from EULAR 2026 in London, one of the world’s largest rheumatology conferences, to explain how meetings like this help shape the future of patient care. The episode explores why conferences matter not just for doctors and researchers, but for patients and advocacy organizations as well. Steven discusses how practicing clinicians learn about the latest medical advances, how researchers connect directly with physicians treating patients every day, and why organizations like GHLF play an important role in bringing real-world patient experiences into scientific and medical conversations. The episode also highlights several emerging themes already generating excitement at EULAR this year, including the growing role of artificial intelligence in rheumatology and the potential future of CAR-T and cell therapies for autoimmune diseases like lupus and rheumatoid arthritis. Most importantly, the conversation explains how scientific innovation ultimately connects back to what matters most: improving the daily lives of patients. Contact Our HostSteven Newmark, Chief of Policy at GHLF: snewmark@ghlf.orgA podcast episode produced by Amelia Violet Prouse, Associate Podcast & Video Producer at GHLF.We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to podcasts@ghlf.orgListen to all episodes of The Health Advocates on our website or on your favorite podcast channel. See omnystudio.com/listener for privacy information.

Send us Fan MailPrime Day isn't just about massive discounts, it's about margin protection and long-term audience building. In this video, we break down why a "Low-Discount" strategy often yields higher net profit and how to use technical tools like Amazon Marketing Cloud (AMC) and Brand Tailored Promotions to capture sales after the event ends.Get help from My Amazon Guy to grow your Amazon sales. https://bit.ly/4jMZtxu#AmazonPrimeDay #AmazonFBA #AmazonSellers #AmazonPPC #amazonmarketing Want free resources? Dowload our Free Amazon guides here:Amazon Receiving Delay Guide: https://hubs.ly/Q04cdD4c0Amazon Catalog Spring Cleaning: https://hubs.ly/Q046BVfp0Amazon Proft Margin Defense 2026: https://hubs.ly/Q042trRH0Amazon SEO Toolkit 2026: https://bit.ly/4oC2ClTAmazon Seller Strategy Report 2026: https://bit.ly/3YN1RME2026 Ecommerce Website & SEO Readiness Checklist: https://hubs.ly/Q04btghf0Amazon 2026 PPC guide: https://bit.ly/4lF0OYXTimestamps00:00 Should You Actually Discount on Prime Day? 01:21 The "Added to Cart" Secret Tactic 02:54 Why the Account-Wide View is Killing Your Profit 03:55 Testing Campaigns Before the Big Event 04:12 AMC Audience Insights: Building Your Post-Prime Funnel 05:00 Summary & Next Steps for Your Brand-----------------------------------------------------------------------------------------Follow us:LinkedIn: https://www.linkedin.com/company/28605816/Instagram: https://www.instagram.com/stevenpopemag/Pinterest: https://www.pinterest.com/myamazonguys/Twitter: https://twitter.com/myamazonguySubscribe to the My Amazon Guy podcast: https://podcast.myamazonguy.comApple Podcast: https://podcasts.apple.com/us/podcast/my-amazon-guy/id1501974229Spotify: https://open.spotify.com/show/4A5ASHGGfr6s4wWNQIqyVwSupport the show

durée : 00:51:59 - Les informés de franceinfo - Tous les soirs, les informés de franceinfo débattent de l'actualité autour de Victor Matet. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

“I think it’s the most exciting period in cancer discovery and development that I’ve experienced over the last 25 years,” says Susan Galbraith, executive vice president of oncology R&D at AstraZeneca. Galbraith joins Bloomberg Intelligence analyst Sam Fazeli fresh from the ASCO conference to unpack how ctDNA, earlier intervention and next-generation oncology platforms could reshape cancer care. They discuss AstraZeneca’s Stride regimen in liver cancer, Serena-6 in breast cancer, progress in pancreatic cancer and the company’s push across ADCs, bispecifics, CAR-T and radio conjugates.See omnystudio.com/listener for privacy information.

Xavier Barreto, presidente da APAH, considera que é necessário contratar pessoas com experiência e com currículo, que tenha perfil de gestor, independentemente de ser filiado num partido ou não.See omnystudio.com/listener for privacy information.

In this episode of On The Line, host Matt Gurney is joined by two guests for conversations about politics, technology, and trust.This episode of On The Line is brought to you by BioCanRX, a federally funded, not-for-profit Canadian research network that specializes in bringing Canadian cancer immunotherapy research from the lab all the way to patients in clinical trials in Canada. Can science help your immune system detect and destroy cancer? Immunotherapy is about assisting your immune system in identifying unhealthy cells –– especially cancer –– that have found a way to evade detection. One way researchers are doing this is through something called CAR T. They draw your blood, isolate one type of your immune cells –– T-Cells –– and use a virus to inject genetic instructions that cause them to grow new receptors designed specifically to bind with your particular cancer. When those cells are re-infused into your body, they hopefully will be able to find and destroy your cancer.  The results are promising. In one of the 16 trials BioCanRx funds based on Canadian technology, CLIC-01, the median number of months remaining for patients with late-stage leukemia and lymphoma tripled. For some, the response was even bigger: they went from being out of options to cancer free, and have stayed that way for several years.Many questions remain — and we're working on answering them. You'll hear more over the summer. For now, go to BioCanRX.com to learn more.First up is PJ Fournier of 338Canada for a look at the latest political numbers. They discuss the good news for Mark Carney, the bad news for Pierre Poilievre, and why the Liberal numbers may not be quite as strong as they first appear. The conversation then turns to Quebec, where the next provincial election is shaping up to be one of the strangest contests either man can remember. Fournier struggles to find a historical comparison. They also discuss softening support for separation in Quebec, how that compares with developments in Alberta, and a point Matt makes that PJ suspects may not be especially popular with Quebec nationalists — even if he doesn't disagree with it.Then Matt is joined by David Shipley of Beauceron Security for a discussion about artificial intelligence, social media, and the growing gap between technological change and political institutions. How much of the current AI boom is real, and how much is hype fuelled by companies racing toward public offerings? Shipley argues that Canadians deserve greater transparency around the Tumbler Ridge case, while Matt notes that he can't even get straightforward answers about transit delays, leaving him less than optimistic about the prospects for accountability.This episode is also brought to you by the Forest Products Association of Canada. A stronger forest industry starts with predictability. Mill modernization, bioenergy, mass timber, and advanced biomaterials all depend on reliable access to usable Canadian wood fibre, workable timelines, and clear rules. Provinces lead forest management, and the federal role should be coordinated, complementary, and focused on results. Every unnecessary delay makes it harder to keep jobs and attract investment. For a sector rooted in communities, regulatory efficiency is economic policy. Learn more at FPAC.ca.The conversation also examines how major social media platforms are being exploited for fraud and manipulation, an issue Shipley has been testifying about. The core problem, he argues, is that the internet moves at the speed of light while politicians move at the speed of Parliament. That mismatch is creating vulnerabilities that are only getting worse. The episode closes with a warning to Albertans heading into a possible referendum campaign: Shipley isn't telling anyone how to vote, but he is urging people to be extremely careful about what they believe online. Foreign interference efforts are already arriving, and they're unlikely to get less sophisticated from here.This episode is also brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That's why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers.To learn more, visit ap1000.cameco.com.Check out our main page at ReadTheLine.ca and be sure to like and subscribe. We'll be back on Friday with another episode of The Line Podcast.#OnTheLine #CanadaPolitics #338Canada #PJFournier #MarkCarney #PierrePoilievre #QuebecPolitics #AlbertaPolitics #ArtificialIntelligence #CyberSecurity #DavidShipley #ForeignInterference #MattGurney

On this week's episode, Yaron Werber, Tess Cameron, SamFazeli, and Brian Skorney kick off with a look at markets, noting that while AI remains hot, biotech may be cooling amid anticipated tech IPOs. The co-hosts note that biotech saw a significant recovery over the past year driven by M&A and improving sentiment, highlighting that the XBI has remained remarkably stable. The discussion then turns to policy, where momentum to expand the COINS Act into biotech raises concerns. The group highlights the need to distinguish between manufacturing supply chains, where national security risks are real, and innovation ecosystems, where restricting capital flows could slow drug development and shift advantage outside of the US. Recapping the highlights from ASCO 2026, Akeso/Summit's ivonescimab showed meaningful survival benefits, while Revolution Medicines' KRAS program in pancreatic cancer stood out as a breakthrough, receiving a standing ovation at the conference. In breast cancer, the focus was centered on emerging CDK4 selective inhibitors from Pfizer and others. Grail's multi-cancer early detection readout was also discussed, along with in vivo CAR-T data from Kelonia that showed strong early responses but raised durability questions. *This episode aired on June 5, 2026.

In a live X Spaces discussion hosted by CancerNetwork® in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT), Marc J. Braunstein, MD, PhD, and Sofia Zahid, MD, highlighted noteworthy presentations and abstracts in hematologic oncology at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Together, they discussed the data that may shake up clinical practice across different multiple myeloma, leukemia, and lymphoma populations.Braunstein is an associate professor in the Department of Medicine and course co-director of the Hematology/Oncology System at NYU Grossman Long Island School of Medicine, as well as the fellowship program director of Hematology/Oncology at NYU Langone Health. Zahid is a first-year fellow at NYU Grossman Long Island School of Medicine.The discussion focused on the following abstracts:·      Abstract 7512o   Combining belantamab mafodotin-blmf (Blenrep) with daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone produced rapid activity among patients with transplant-ineligible newly diagnosed multiple myeloma in the phase 1/2 BelaDRd study (EUCT-2024-515634-32).o   The progression-free survival (PFS) benefits observed in the trial support further evaluation of the quadruplet in a phase 3 study compared with other novel combination regimens in NDMM.·      Abstract 6505o   Revumenib (Revuforj) maintenance therapy after allogeneic stem cell transplantation showed feasibility in a heavily pretreated cohort of patients with acute myeloid leukemia (AML).o   Outcomes appeared favorable vs historical cohorts, supporting prospective assessment of maintenance menin inhibition among those with AML.·      Abstract 1503o   In a retrospective analysis of electronic medical records for 293 patients who received CAR T-cell therapy for lymphoma (n = 175), multiple myeloma (n = 106), or B-cell acute lymphoblastic leukemia (n = 12), outpatient monitoring was associated with significantly fewer hospital days without increased emergency department visits or 30-day mortality.o   These findings show the potential for lower healthcare utilization for patients who receive CAR T-cell therapy in the outpatient setting.·      Abstract LBA7000o   Adding tafasitamab (Monjuvi) and lenalidomide to rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) significantly improved PFS vs R-CHOP alone among those with newly diagnosed diffuse large B-cell lymphoma (DLBCL) in the phase 3 frontMIND trial (NCT04824092).o   The data may support tafasitamab plus lenalidomide and R-CHOP as a potential new standard of care in the frontline treatment of patients with cell-of-origin subtypes of high-risk DLBCL.References Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, et al. Belantamab mafodotin with daratumumab, lenalidomide, and dexamethasone in transplant-ineligible, newly diagnosed multiple myeloma patients: phase 1/2 BelaDRd study. J Clin Oncol. 2026;44(suppl 16):7512. doi:10.1200/JCO.2026.44.16_suppl.7512 Goulart H, Okeleji O, DiNardo CD, et al. Revumenib as maintenance for AML following allogeneic stem cell transplantation. J Clin Oncol. 2026;44(suppl 16):6505. doi:10.1200/JCO.2026.44.16_suppl.6505 Bowen SG, Abdallah N, Pritchett JC, et al. Impact of outpatient CAR T-cell therapy administration on healthcare utilization in patients with hematologic malignancies. J Clin Oncol. 2026;44(suppl 16):1503. doi:10.1200/JCO.2026.44.16_suppl.1503 Lenz, G, Trněný M, Burke JM, et al. frontMIND: phase 3 study of tafasitamab (Tafa) plus lenalidomide (Len) and R-CHOP for patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2026;44(suppl 17):LBA7000. doi:10.1200/JCO.2026.44.17_suppl.LBA7000

Christine Kelly revient, sans concession, sur tous les sujets qui font l'actualité. Vous voulez réagir ? Appelez le 01.80.20.39.21 (numéro non surtaxé) ou rendez-vous sur les réseaux sociaux d'Europe 1 pour livrer votre opinion et débattre sur grandes thématiques développées dans l'émission du jour.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Today, we're putting The Tonearm's needle on Stephen Emmer, a Dutch composer and musician based in Amsterdam. Stephen came up in the late 70s post-punk underground, and his band Minny Pops was the first international act signed to Factory Records. He is a curious genre-explorer who has worked with Lou Reed, Chaka Khan, Tony Visconti, Trevor Horn, Flood, and many others.His latest album, Asymmetrical Dot, is a chamber work rooted in his Dutch-Indonesian heritage, built around sustained tones, wordless vocals, vibraphone, and strings. The record came out of a year when his mother died, and his first grandson was born, and the contracting themes of grief and arrival appear throughout the work.We cover the album, his hearing loss, and why he walked away from commercial work to make the most personal music of his career.(The musical excerpts heard in the interview are from Stephen Emmer's Asymmetrical Dot)—Dig Deeper• Artist and Albums:Visit Stephen Emmer at stephenemmer.com and follow him on Bluesky, Instagram, and YouTubePurchase Stephen Emmer's album Asymmetrical Dot from Bandcamp or Qobuz and listen on your streaming platform of choiceThe two previous installments in the 'introspective trilogy': Maison Melody (2020) and Mt. Mundane (2024)• Key Collaborators:Tony Visconti — Producer of Recitement; longtime producer of David BowieBeth Hirsch — Vocalist and co-writer on Asymmetrical Dot, Track 5; best known for AIR's Moon SafariFernando Aponte — Grammy-winning mixing engineer, HoustonEverton Nelson — Concertmaster and violinist; has performed with the LSO, BBC Concert Orchestra, and on recordings for Radiohead, U2, and Paul McCartneyPatricia Sullivan — Mastering engineer at Bernie Grundman Mastering, Los Angeles• *Recitement* and Its Voices:Recitement — Emmer's 2007 spoken-word album, produced by Tony Visconti.Ken Nordine — Voice-over artist and "Word Jazz" pioneer; voiced "Absolutely Grey" on RecitementColors — Ken Nordine's 1966 album, originally commissioned as radio spots for the Fuller Paint CompanyLou Reed — Rock musician and poet; voiced "Passengers" on RecitementAllen Ginsberg — Beat poet; voiced "Disconnected" on RecitementRichard Burton — Welsh actor; voiced "The Leaden Echo" and "Boy with a Cart" on Recitement• Musical Influences and References:Gamelan — Traditional Indonesian percussion ensemble; central to the sonic concept of Asymmetrical DotDave Brubeck — American jazz pianist; one of the first musicians Emmer heard as a child, via his mother's ballet teachingHeitor Villa-Lobos — Brazilian composer; among the diverse influences Emmer's mother brought to her ballet classesClaude Debussy and Gamelan — Referenced by Emmer as a historical predecessor in integrating gamelan into Western composition• Contextual References:Holiday on Ice — International touring ice show for which Emmer served as music directorMotörhead — British heavy metal band; Emmer's hearing damage traces to a backstage encounter with their sound systemCharles Ives — American modernist composer who ran a successful insurance business alongside his musical career; referenced in the episode's discussion of portfolio careersAmbon, Indonesia — Island in the Maluku province of Indonesia, historically known as Amboina; birthplace of Emmer's mother and inspiration for the album's track "Amboina (for Roekie Aronds)"—Dig into this episode's complete show notes at podcast.thetonearm.com—• Did you enjoy this episode? Please share it with a friend! You can also rate The Tonearm ⭐️⭐️⭐️⭐️⭐️ and leave a review on Apple Podcasts. • Subscribe! Be the first to check out each new episode of The Tonearm in your podcast app of choice. • Looking for more? Visit podcast.thetonearm.com for bonus content, web-only interviews + features, and the Talk Of The Tonearm email newsletter. You can also follow us on Bluesky, Mastodon, YouTube, and LinkedIn. • Be sure to bookmark our online magazine, The Tonearm! → thetonearm.com Hosted on Acast. See acast.com/privacy for more information.

Today, we're putting The Tonearm's needle on Stephen Emmer, a Dutch composer and musician based in Amsterdam. Stephen came up in the late 70s post-punk underground, and his band Minny Pops was the first international act signed to Factory Records. He is a curious genre-explorer who has worked with Lou Reed, Chaka Khan, Tony Visconti, Trevor Horn, Flood, and many others.His latest album, Asymmetrical Dot, is a chamber work rooted in his Dutch-Indonesian heritage, built around sustained tones, wordless vocals, vibraphone, and strings. The record came out of a year when his mother died, and his first grandson was born, and the contracting themes of grief and arrival appear throughout the work.We cover the album, his hearing loss, and why he walked away from commercial work to make the most personal music of his career.(The musical excerpts heard in the interview are from Stephen Emmer's Asymmetrical Dot)—Dig Deeper• Artist and Albums:Visit Stephen Emmer at stephenemmer.com and follow him on Bluesky, Instagram, and YouTubePurchase Stephen Emmer's album Asymmetrical Dot from Bandcamp or Qobuz and listen on your streaming platform of choiceThe two previous installments in the 'introspective trilogy': Maison Melody (2020) and Mt. Mundane (2024)• Key Collaborators:Tony Visconti — Producer of Recitement; longtime producer of David BowieBeth Hirsch — Vocalist and co-writer on Asymmetrical Dot, Track 5; best known for AIR's Moon SafariFernando Aponte — Grammy-winning mixing engineer, HoustonEverton Nelson — Concertmaster and violinist; has performed with the LSO, BBC Concert Orchestra, and on recordings for Radiohead, U2, and Paul McCartneyPatricia Sullivan — Mastering engineer at Bernie Grundman Mastering, Los Angeles• *Recitement* and Its Voices:Recitement — Emmer's 2007 spoken-word album, produced by Tony Visconti.Ken Nordine — Voice-over artist and "Word Jazz" pioneer; voiced "Absolutely Grey" on RecitementColors — Ken Nordine's 1966 album, originally commissioned as radio spots for the Fuller Paint CompanyLou Reed — Rock musician and poet; voiced "Passengers" on RecitementAllen Ginsberg — Beat poet; voiced "Disconnected" on RecitementRichard Burton — Welsh actor; voiced "The Leaden Echo" and "Boy with a Cart" on Recitement• Musical Influences and References:Gamelan — Traditional Indonesian percussion ensemble; central to the sonic concept of Asymmetrical DotDave Brubeck — American jazz pianist; one of the first musicians Emmer heard as a child, via his mother's ballet teachingHeitor Villa-Lobos — Brazilian composer; among the diverse influences Emmer's mother brought to her ballet classesClaude Debussy and Gamelan — Referenced by Emmer as a historical predecessor in integrating gamelan into Western composition• Contextual References:Holiday on Ice — International touring ice show for which Emmer served as music directorMotörhead — British heavy metal band; Emmer's hearing damage traces to a backstage encounter with their sound systemCharles Ives — American modernist composer who ran a successful insurance business alongside his musical career; referenced in the episode's discussion of portfolio careersAmbon, Indonesia — Island in the Maluku province of Indonesia, historically known as Amboina; birthplace of Emmer's mother and inspiration for the album's track "Amboina (for Roekie Aronds)"—Dig into this episode's complete show notes at podcast.thetonearm.com—• Did you enjoy this episode? Please share it with a friend! You can also rate The Tonearm ⭐️⭐️⭐️⭐️⭐️ and leave a review on Apple Podcasts. • Subscribe! Be the first to check out each new episode of The Tonearm in your podcast app of choice. • Looking for more? Visit podcast.thetonearm.com for bonus content, web-only interviews + features, and the Talk Of The Tonearm email newsletter. You can also follow us on Bluesky, Mastodon, YouTube, and LinkedIn. • Be sure to bookmark our online magazine, The Tonearm! → thetonearm.com Hosted on Acast. See acast.com/privacy for more information.

That chair in your online cart is way over budget. But there's a trick to help you snag discounts off at checkout. And Johanna was moving to Spain with a new baby and a house full of furniture to sell. Fed up with scammers on Facebook Marketplace, she used AI to make her own selling site. Zero coding experience. Learn more about your ad choices. Visit megaphone.fm/adchoices

Fontes do episódio aqui:⁠https://portal.afya.com.br/podcasts/afya-news/06-06-2026Nesta edição de resumo semanal, revisamos os principais acontecimentos que movimentaram a medicina nos últimos dias, desde as barreiras de biossegurança até saltos em biotecnologia. Analisamos o desfecho das investigações de Ebola no Brasil e o reconhecimento do país como livre de febre aftosa sob a ótica de One Health. Na oncologia, destacamos o impacto do daraxonrasib na ASCO, a ampliação do Tevimbra® e o futuro das terapias CAR-T in vivo e radiofármacos. Por fim, abordamos o lançamento da plataforma Medicina Segura pelo CFM, o novo antiviral pós-exposição contra a COVID-19 e a gamificação no treinamento médico. Afya News. Informação médica confiável e atualizada no seu tempo.

Each year, the global oncology community flocks to Chicago to convene at the American Society of Clinical Oncology’s annual meeting for a weekend of buzzy data drops, practice-changing posters and insightful sessions. In this week’s episode of "The Top Line," Fierce Biotech and Fierce Pharma’s Darren Incorvaia, Zoey Becker and Angus Liu break down the biggest takeaways from their weekend of reporting live from the Windy City. From “nutty” in vivo CAR-T data to a historic first for a Chinese biotech asset, ASCO 2026 reflected new and continuing trends within the evolving state of cancer care today. To learn more about the topics in this episode: ASCO: Revolution Medicines confident in RAS leadership as rivals square up ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout ASCO preview: With expectations jacked up, Akeso's ivonescimab to face scrutiny in high-stakes plenary See omnystudio.com/listener for privacy information.

Fontes do episódio aqui:⁠https://portal.afya.com.br/podcasts/afya-news/05-06-2026Nesta sexta-feira, analisamos atualizações em endocrinologia reprodutiva, uma revolução na terapia celular oncológica e o papel dos jogos sérios no julgamento clínico. Abordamos as diretrizes atualizadas da American Thyroid Association, que estabelecem valores de referência por trimestre para TSH e T4, priorizando o rastreamento direcionado. Detalhamos os dados promissores da nova terapia CAR-T in vivo da Legend Biotech para linfoma não-Hodgkin, que gera as células de defesa diretamente dentro do corpo do paciente. Por fim, discutimos no Radar um estudo do JAMA que comprova como o jogo eletrônico Night Shift reduziu erros médicos e a subestimativa de traumas em idosos na emergência. Afya News. Informação médica confiável e atualizada no seu tempo.

They also explore exciting new therapies like CAR T-cell treatment, along with practical advice on self-advocacy, building the right healthcare team, and what it truly means to thrive while living with a rheumatic disease. Episode at a glance: Why Dr. Singh became a rheumatologist after watching her grandmother struggle with osteoarthritis What current research shows about biologics and cancer risk Why most cancer fears surrounding arthritis medications are often more complicated than they seem How cancer immunotherapy can sometimes trigger inflammatory arthritis The importance of communication between rheumatologists, oncologists, and other specialists What patients should know about skin cancer, lymphoma, and other cancer risks The emerging role of CAR-T cell therapy in autoimmune diseases Why researchers are increasingly optimistic about long-term remission and potential cures Advice for newly diagnosed patients navigating inflammatory arthritis What it means to truly "thrive" while living with rheumatic disease Medical disclaimer:  All content found on Arthritis Life public channels was created for generalized informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Episode Sponsors Rheum to THRIVE, an online course and support program Cheryl created to help people with rheumatic disease go from overwhelmed, confused and alone to confident, supported and connected. See all the details and join the program or waitlist now!  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We love to hear from our listeners. Send us a message.In episode 130 of Cell & Gene: The Podcast, Dr. Naji Gehchan, Chief Medical and Development Officer at Kyverna Therapeutics, joins Host Erin Harris to outline the company's mission to apply CAR T-cell therapy beyond oncology to treat severe autoimmune diseases, highlighting promising Phase 2 data from its investigational therapy, Miv-cel, in stiff person syndrome (SPS). Dr. Gehchan explains that Miv-cel works by deeply depleting pathogenic B cells and enabling a broad immune reset, differentiating it from conventional therapies that require ongoing management. As Kyverna advances a rolling BLA submission, Dr. Gehchan positions this milestone as potentially historic, both for SPS patients and for the broader cell therapy field, signaling an inflection point where CAR T could transform autoimmune disease care in the same way it has oncology.Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

In this Review series episode, Blood associate editor Dr. Diane Krause interviews contributing authors from the Review Series on Clonal tracking in Hematopoiesis published in volume 147 issue 23 of Blood. Dr. Alejo E. Rodriguez-Fraticelli speaks to the development of his paper, "Clonal tracing of blood stem cells across mouse and human lifespans”, which provides a detailed overview of the experimental approaches that make clonal analysis possible, and which approaches are most appropriate to use to address specific questions. Dr. Shalin H. Naik speaks about how different clonal tracking approaches have been used to address the central question of clonal fate specification of stem and progenitor cells to specific lineages in “The evolution of hematopoietic models through a clonal lens”. Finally, Dr. Federico Gaiti speaks about “Methylation-based lineage tracing in cancer”, which takes these ideas into the context of cancer, focusing on how DNA methylation can be used to reconstruct clonal relationships.  

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most significant advancements in scientific research, clinical trials, and regulatory landscapes within the industry. These developments are shaping the future of patient care and drug development significantly. Starting with Legend Biotech's LB2501, which achieved an impressive 100% response rate in a Phase 1 study for non-Hodgkin lymphoma using in vivo CAR T-cell therapy. This breakthrough highlights the transformative potential of CAR T-cell therapies in oncology, especially for B-cell lymphomas. Such success opens the door for accelerated regulatory pathways, offering hope to patients with limited treatment options. In another key development, JJP Biologics shared positive interim data from its Phase 1b trial of nebaprubart targeting CD89 in linear IgA disease. This monoclonal antibody is promising in treating autoimmune conditions by targeting specific disease mechanisms. Meanwhile, GSK's Velzatinib (IDRX-42) achieved a 61% response rate in Phase 1/1b trials for gastrointestinal stromal tumors, showing efficacy against cases resistant to treatments like imatinib. Johnson & Johnson's Nipocalimab met its primary endpoint in a Phase 2 study for systemic lupus erythematosus, underscoring the potential of FcRn blockade in managing autoimmune diseases. Zenas Biopharma's Phase 3 data for Obexelimab targeting CD19/FcγRIIB in IgG4-related disease further emphasizes the role of targeted therapies in managing complex autoimmune disorders. On the regulatory front, Foundation Medicine's FoundationOne Blood Test received FDA approval as a companion diagnostic for Pfizer's Talzenna (talazoparib) to treat prostate cancer with homologous recombination repair gene mutations. This approval underscores the growing importance of precision medicine and companion diagnostics in tailoring cancer treatments based on genetic profiles. Additionally, Lupin and Natco Pharma secured FDA approval for their generic version of Eribulin Mesylate Injection, essential for reducing healthcare costs and improving patient access to vital therapies. Eli Lilly's collaboration with Ascidian Therapeutics focuses on RNA exon editing for kidney diseases, potentially revolutionizing treatment approaches by correcting genetic errors at the RNA level. This partnership reflects a burgeoning interest in RNA-based therapies and their capacity to address unmet medical needs. Regeneron expanded its pact with CytomX Therapeutics to develop conditionally active bispecific antibodies, emphasizing innovation in oncology drug discovery. Such collaborations combine expertise across companies to expedite cutting-edge therapies' development. In terms of funding, NewLimit's successful $435 million Series C round aims to advance epigenetic reprogramming medicine towards human trials. This initiative highlights the burgeoning field of aging biology and its implications for extending healthy human lifespan through innovative therapeutic approaches. Similarly, Immu Biosciences raised $53 million to enhance its immunology platform using AI/ML technologies, underscoring AI and machine learning's critical role in accelerating drug development processes. Turning our gaze towards China's expanding influence on the global biotech stage, Akeso's presentation at ASCO 2026 marked a significant milestone as it became the first-ever Chinese dataset featured in a plenary session. This achievement underscores China's growing prominence in biotechnology and highlights its commitment to advancing innovative medical solutions globally. Simultaneously, Gilead's strategic partnership with Cencora aims to enhance access to CAR-T therapies like Yescarta and Tecartus by expanding their network of treatment centers. CAR-T therapies represent a paradigm shift in cancer treatment by offering personalized options for certain types of cancer. Despite challenges such as Roche's setbacks with its oral SERD drug giredestrant in breast cancer trials, innovation continues unabated. Zevra Therapeutics' launch of Miplyffa for Niemann-Pick disease type C exemplifies efforts to transform rare disease markets by improving patient outcomes through increased access and tailored treatment strategies. Finally, Eli Lilly's acquisition spree reflects broader trends where pharmaceutical companies increasingly integrate Chinese innovations into their development pipelines. This period marks a transformative phase characterized by collaboration between global pharma giants and Chinese biotechs, signaling an era where innovation is globalized and aimed at addressing critical healthcare challenges worldwide. These advancements reflect a dynamic period of innovation within the pharmaceutical and biotech industries. The focus on personalized medicine, targeted therapies, and groundbreaking technologies like RNA editing indicates a shift towards more precise treatment modalities. As these discoveries transition from research phases to clinical applications, they hold the potential to transform patient care significantly. Strategic partnerships and substantial funding initiatives illustrate a robust ecosystem supporting these innovations' rapid advancement. As regulatory bodies continue approving novel therapeutics and diagnostics, the emphasis on personalized healthcare will likely drive future developments, ultimately leading to improved patient outcomes worldwide. As we continue navigating these developments, it's clear that the pharmaceutical and biotech sectors are on the cusp of transformative breakthroughs that promise to redefine healthcare delivery across multiple domains. Thank you for tuning into Pharma Daily; stay informed and stay ahead.Support the show

This week, we discuss left atrial appendage closure for atrial fibrillation, oxygen strategies in respiratory failure, an all-oral treatment for acute myeloid leukemia, CAR T-cell therapy enabling kidney transplantation, and a case of a neuroepithelial tumor that developed after gene therapy. We review childhood vaccine hesitancy, follow a complex diagnostic case, and examine Perspectives on corporatization in medicine, famine and war, and the future of health care systems.

Rob explains why he missed the bonus show. Which golf predictions came true? Rob has new golf rival, Frank from Myrtle Beach. Justin took Gavin skeet shooting. One of them is awful. Joe calls Jackson about the house's water quality. 

In this week's Omni Talk Retail Fast Five sponsored by the A&M Consumer and Retail Group, Mirakl, Ocampo Capital, Quorso and Veloq, Chris Walton and special guest Shelley Huff, former CEO of Serta Simmons Bedding and co-founder of The Interval, discussed: • Google unveiling its new Universal Cart that allows shoppers to add products across retailers and channels into a single AI-powered shopping experience, and whether it represents the biggest long-term threat yet to Amazon's commerce dominance: https://www.retaildive.com/news/google-launches-cross-retailer-universal-cart/820957/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202026-05-26%20Retail%20Dive%20Newsletter%20%5Bissue:85275%5D&utm_term=Retail%20Dive • Walmart rolling out a new prepaid consolidation program that simplifies inbound logistics for suppliers, and why both Chris and Shelley see it as a rare win-win for retailers and vendors alike: https://www.supplychaindive.com/news/walmart-rolling-out-simplified-inbound-logistics-for-suppliers/821111/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202026-05-27%20Supply%20Chain%20Dive%20%5Bissue:85359%5D&utm_term=Supply%20Chain%20Dive • SPAR Austria expanding its use of inventory robots to additional stores, and what the move signals about the growing role of robotics in improving store operations and inventory accuracy: https://spar-international.com/news/spar-austria-expands-inventory-robot-trial/ • Walmart reporting explosive growth in store-fulfilled delivery, including record-fast delivery times and surging drone deliveries, and which metrics matter most as the company battles Amazon for customer loyalty: https://www.supplychaindive.com/news/walmart-store-fulfilled-deliveries-getting-faster/821126/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202026-05-28%20Supply%20Chain%20Dive%20%5Bissue:85420%5D&utm_term=Supply%20Chain%20Dive • AWS launching a new agentic shopping assistant solution that allows retailers to deploy Amazon-powered conversational shopping experiences, and the critical question every retailer must answer about who owns the customer intelligence layer: https://www.aboutamazon.com/news/aws/aws-agentic-shopping-assistant-retailers And RADAR CEO Spencer Hewett also dropped by for 5 Insightful Minutes to discuss his company's $170 million raise, connected stores at scale, and why real-time retail is finally becoming a reality. There's all that, plus sunrise hikes in Arizona, European grocery innovation, The Rock's latest product launch, and why younger shoppers may be more comfortable letting AI make decisions for them. P.S. Be sure to check out all our other podcasts from the past week here, too: https://omnitalk.blog/category/podcast/ P.P.S. Also be sure to check out our podcast rankings on Feedspot: https://podcasts.feedspot.com/retail_podcasts/ Music by hooksounds.com

Rich and Greg Komen decided they wanted a empire and then went a built it. Not the normal path, but… Cinnabon! Dave Young: Welcome to the Empire Builders Podcast, teaching business owners the not so secret techniques that took famous businesses from mom and pop to major brands. Stephen Semple is a marketing consultant, story collector, and storyteller. I’m Stephen’s sidekick and business partner, Dave Young. Before we get into today’s episode, a word from our sponsor, which is, well, it’s us, but we’re highlighting ads we’ve written and produced for our clients. So here’s one of those. [Maven Roofing Ad] Dave Young: Hey, welcome back to the Empire Builders Podcast. Dave Young here alongside Stephen Semple and today we’re going to unpack the story of Cinnabon. Stephen Semple: Yes. Dave Young: Now Stephen told me the topic for today. He said, “Now I know you know about this one.” And then he said Cinnabon. And I’m like, “You know, actually I don’t.” Stephen Semple: Really? Dave Young: I’m really more … You know what I’m really more interested in is why you- Stephen Semple: Have you never gone to a shopping mall? Dave Young: … why you think I would know Cinnabon? Just one look at me and you go, “That guy’s seen some Cinnabon.” Stephen Semple: Well, they only have like 1,800 locations. Dave Young: Okay. Here’s the deal. Here’s the deal. Remember I spent the first 50 years of my life in a town that didn’t have a mall. Stephen Semple: I know, but you’ve grown up since then, Dave. Dave Young: I know. Stephen Semple: They’re still around. It’s not like … Dave Young: They’re around, but we would steer our children away from the Cinnabon when we went to a mall. It was like, “No, we’re not just making you all sticky with frosting.” So the times I’ve had any kind of Cinnabon product, and they’re in what, Wendy’s or places now. Maybe it’s not Wendy’s. Is it Wendy’s? Stephen Semple: I’m not sure. Dave Young: They’re somewhere, you can buy Cinnabon stuff. Maybe it’s Taco Bell. I don’t know. Again, remember, I’m not as familiar with Cinnabon as you thought I was. Dive right in, Stephen. Stephen Semple: You’re getting kind of defensive here, Dave. Dave Young: Edumicate us on the Cinnabons. Stephen Semple: Well, they are now like 1800 locations worldwide, 50 countries. They’re now part of go to foods, huge margins in this type of business. And what’s really interesting, all built around one product. And they sell over two million buns a day, just huge. But this is a very different story than pretty much all of the other stories we’ve done because most of the stories we’ve done have started with a problem that the entrepreneur faced. They solved that problem and turned it into a business. Many of them did not start with, “I’m going to do this thing and make it a business.” It’s like, “I’m going to do this thing. Oh, I should turn it into a business.” Dave Young: “Oh, hey, look, people seem to like this.” Yeah. Stephen Semple: Right. It was started by Rich Komen and his son, Greg. And Rich was an entrepreneur who had been involved basically in the food industry, developing franchises, things along that lines. And he got into the food business after graduating because he saw concessions in the malls and said, “These are crappy.” Dave Young: Right. Yeah. Stephen Semple: Because this was back in the early 80s when malls were just … And the food court in the mall was just sort of getting going. And he saw- Dave Young: Like a pretzel or a corn dog. Stephen Semple: He saw the growth potential and so his idea was to develop a food offering, but he was a retail strategist, not a baker. And he set out to create a product that he wanted to be so irresistible it could sell itself in this super competitive environment, the shopping mall, right? Dave Young: Yeah. Stephen Semple: So it was built all from the perspective of the consumer, not the kitchen. And what he wanted to do is have an idea that right from the start he could take national. So it’s 1985 and Rich and Greg Komen, who are [inaudible 00:04:53] father and son team wanted to just basically build this national company and he saw this growth potential in the food court space. He saw that exploding and he had been approaching actually a lot of malls to get a spot in the mall and he finally got one who was willing to give him a chance. Now he needed a concept. This guy kind of went about it in a weird way. I’ll get the mall space and then I’ll find the concept. Dave Young: I’ll find something to sell people. People seem to like these cinnamon rolls. Well, all right, yeah. Stephen Semple: So he’s literally on a business trip to Kansas City and he stumbles across this single kiosk selling this sweetbread that’s in a spiral with a glaze and cinnamon called T.J. Cinnamons. Dave Young: T.J. Cinnamons. Okay. Stephen Semple: Yeah. Which is owned by Rice and his wife, Joyce. Rice is a cameraman. Joyce is a school teacher. Rich wants to buy the franchising rights and turn it into a national chain. Dave Young: Wow. Stephen Semple: And he pitches them on the idea of moving fast and building big. He’s so confident that he’s going to get the rights he commits to that lease in the food stall of the shopping mall. They get a little overwhelmed. Dave Young: No kidding. Stephen Semple: And tell Rich, “We need to kind of think about this,” and they actually decide no. Dave Young: Yeah. Stephen Semple: Now Rich has got a little bit of a dilemma. He’s opening in six months and he’s got no name, no recipe. He’s got nothing. Dave Young: Well, look- Stephen Semple: He’s got nothing. Dave Young: Here’s what I know. Ask any grandma in America, find 20 of them and just pick the one that’s got the best recipe. Stephen Semple: Well, what he does is he enlists Jerilyn Brusseau who’s known for exceptional baked goods. Because remember, he is from the industry. And so he and his son go about trying to develop a better bun that’s richer, tastier, sweeter than T.J. Cinnamons. It’s like they want to beat T.J. Cinnamons, but trial after trial after trial after trial, they come up short. Tons of recipes, rejects all of them because here’s the other problem is the baking time is taking 30 minutes and what they know is … This is back in the day when customers would tolerate 14 minutes. We’re not going to tolerate that today. So they tried to accelerate the baking, crank the oven temperature, widen the trays. Everything was unworkable. Now here’s the advantage that we have with the fact we’ve got somebody from outside of the baking industry because here’s what Rich discovers is that if it cooks for 14 minutes, the internal temperature gets to 165 degrees, which is considered safe. But by industry standards, it’s not fully cooked, but it’s fluffy, it’s soft, it’s a bit chewy. Dave Young: It’s gooey. Stephen Semple: It’s gooey. And he’s like, “I think this is better.” Dave Young: Yeah, absolutely. Nobody wants a fully baked cinnamon roll. Stephen Semple: Right. But here’s where the problem- Dave Young: Take a bunch of the Pillsbury, pop the thing open and you put them in a pie pan and the ones in the center are the ones everybody’s grabbing, not the baked up dry ones around the edges. Stephen Semple: Right. But here’s the problem. Because it doesn’t do the full baking, the cinnamon flavor was lacking. So they did all sorts of experiments with all sorts of different cinnamons till they came across Sumatra cinnamon. Dave Young: Sumatra cinnamon. Okay. Stephen Semple: Yeah. Because it’ll create that cinnamon flavor without the excessive heat. Other cinnamons needed the heat. Dave Young: Okay. Stephen Semple: So now they got a recipe and they need a name. So they go with bon, which is French for good. Dave Young: It’s good. Yes. Stephen Semple: And cinnamon. Cinnabon. Dave Young: Yeah. I love it. Stephen Semple: And add world-famous because why not? Dave Young: Oh, so it was world-famous from the beginning? Stephen Semple: It was world-famous from the beginning. Dave Young: Stay tuned. We’re going to wrap up this story and tell you how to apply this lesson to your business right after this. [Using Stories To Sell] Dave Young: Let’s pick up our story where we left off and trust me you haven’t missed a thing. Stephen Semple: So now they got a recipe and they need a name. So they go with bon, which is French for good. Dave Young: It’s good. Yes. Stephen Semple: And cinnamon. Cinnabon. Dave Young: Yeah, I love it. Stephen Semple: And add world-famous because why not? Dave Young: Oh, so it was world-famous from the beginning? Stephen Semple: It was world-famous from the beginning. Dave Young: Sure. Cinnamon and good. Everybody loves those. Everybody knows cinnamon and good. Stephen Semple: Yeah. Dave Young: Okay. Stephen Semple: So December 4th, 1985, the first Cinnabon opens in the Seattle SeaTac Mall and it’s an event. They put on a show. Watch the ingredients being mixed, rolled. There’s this cream cheese frosting and it does great. $500 sales in the first day and the second day was even better. Now, Rich learns that T.J. Cinnamon, who rejected him, have decided to franchise and go into malls. Dave Young: Okay. Yeah, sure they did. Stephen Semple: Sure they did. And look, no mall’s going to take both. So he needs to do something that stand out because he’s got to be the better choice. So they decide, he and his son decide they need to use smell. Because anytime the ovens opened or whatnot, they notice the smell and a crowd would gather. So they were like, “Okay, how do we create smell?” Well, they can’t turn off the ventilation. That’s against code. So the first thing it did was they installed systems with lowest possible ventilation allowed. But even then the smell is coming in waves. So they came up with this idea. Why don’t we just bake sugar and cinnamon? Dave Young: Yeah, bake that all the time. Stephen Semple: Bake that all the time. And that’s what they decided to do. So they started baking sugar and cinnamon. When you walk past a Cinnabon, there’s this wafting, delicious, incredible, fresh baked smell coming out of the store that competes with everyone. Like you know it’s there. You haven’t turned the corner in the mall yet and you know it’s there. Dave Young: When you’re walking through a mall with four little children, you smell it and then you’re like, “Hey, let’s walk on the other side to …” Stephen Semple: As far as I know, they are really the first business that I’ve been able to come across that has used scent as part of their marketing tactic. And they basically bottled one of the most delicious scents possible; sugar and cinnamon. Dave Young: I love it. Stephen Semple: By 1998, there’s 500 locations. They’re doing $300 million in sales and they sell for $65 million to the American Retail Group. And Greg, the son, gets to keep eight locations of his choice because he wants to keep running stuff. And then they went on to being the success that they are today. But the thing that I love was there was an advantage to them not being from the baking industry because that whole thing of by a baker, it’s not fully cooked. To them it was like, “Well, it’s done in the speed we need it done. And in fact, it tastes better.” Dave Young: There’s a lot of baked goods that kind of felt like … My oldest daughter in particular made really good toll-house chocolate chip cookies and never baked them fully because they were harder to get off the pan and once they cooled down, they solidified a bit, but they were delicious. They were just soft. And so smarter than professional bakers. Stephen Semple: Yeah. Sometimes you need that outside perspective that makes you think about things differently. But then from a marketing perspective, the other part that I loved is from a marketing perspective, you’re in a mall and back in those days, malls had tons of traffic, good malls still do and they still thought about, how do I attract people to my product? And it was the scent. Dave Young: We tell business owners all the time that good location and good signage is permanent advertising, right? Stephen Semple: Right. And they upped it by adding the smell. Dave Young: Well, the smell is the advertisement. Stephen Semple: Like good location, good signage. And this [inaudible 00:14:04] smell. Dave Young: Yeah, I’m saying that the smell is another sign. Stephen Semple: Oh, absolutely. Absolutely. Dave Young: It’s a sign you don’t have to have your eyes open to see. Stephen Semple: They could have ignored it going, “Yeah, well, when we open the oven…” I loved his observation of, “When we open the oven all of a sudden it attracted people. How do we create this smell all the time?” And I just love the fact that … And I never knew this. I never realized what they just do is bake cinnamon and sugar all day long. I had no idea. Dave Young: I got to try that [inaudible 00:14:35]. Stephen Semple: Just throw a bunch of that in the bottom of the oven and let’s go. I thought it was brilliant. Dave Young: What’s the recipe for that? How long do you leave it in? Is it going to burn? I don’t know how that works, but I love it. Stephen Semple: Oh, in terms of the cinnamon and sugar? I have no idea. I have no idea. Dave Young: Yeah. It’s amazing. So I just made myself a note that I’m going to mention this story the next time I teach Portals in September. Stephen Semple: Oh, there you go. Dave Young: So Portals and the 12 Languages of the Mind. The 12 languages of mind includes smell. It’s an actual language. And this is a great … It’s hard to come up with an example of using smell in marketing. Stephen Semple: Well, especially where these guys are so purposeful about it. They literally went down the path of, “How do we make this happen?” It wasn’t an accident. It wasn’t a byproduct. It was, “Okay, how do we actually make this so it’s happening all the time and that smell is always there?” Dave Young: Yeah. Stephen Semple: You’re right. It is hard to come up with an example. So that’s awesome that you’ll be able to use that for Portals. Dave Young: Yeah, that’ll be fun. It’s in September. If you want to take the Portals class, look at wizardacademy.org. Stephen Semple: It’s an awesome class. I took it and it’s a fabulous class that really gets you thinking about things differently. Dave Young: It’s fun. Stephen Semple: Yeah, it is a fun class. Real, really fun class. Dave Young: All right. Well, thank you for the Cinnabon story. This is sort of a short episode. Anything else you want to ramble about? Stephen Semple: I just want to say folks go over to wizardacademy.org and click on classes and absolutely try to take Dave’s Portal class. It’s a phenomenal class and you’ll get a chance to meet Dave in person. Dave Young: And it’s fun. It’s a weird woo-woo class. I love it. Stephen Semple: Yeah. Dave Young: I love teaching it. I love the material. Always have. Stephen Semple: All right. Awesome. Dave Young: I can’t wait to meet the … Look, let’s have the whole podcast audience show up. That would be fun. Stephen Semple: There you go. Dave Young: Everybody is welcome. Stephen Semple: Everyone, come on down. Hey, before you guys go, I just have one thing I just would like to just add. It’s a little bit of a thought to challenge you in your business. We’ve talked a lot in this episode on Cinnabon about smell and using smell in marketing and it’d be really easy to fall into this trap. Look, what I do is advertising consulting and it’ll be really easy to go, “Oh, I can’t use that idea because my business is advertising consulting.” So here’s what I want you to do. Let’s change our thought. I’m going to challenge all of us a little bit, including myself. Here’s what the question I want you to ask. Given that I’m in advertising consulting, how could I use smell to market my business? Ask yourself that question, just insert your business. Given that I am X business, how could I use smell in the marketing of my business? Just ask yourself that question, let it sit in the mind. Let’s see what happens in the next little while. And hey, you get some really cool [inaudible 00:17:33] insight, share them with me. I’m going to let you go now. Thanks. Dave Young: Thanks for listening to the podcast. Please share us, subscribe on your favorite podcast app and leave us a big, fat, juicy five star rating and review at Apple Podcasts. And if you’d like to schedule your own 90-minute empire building session, you can do it at empirebuildingprogram.com.

In the future, can autoimmune disease become curable? A groundbreaking study from Germany suggests there may be a pathway in some cases. Patients with severe, treatment-refractory lupus who received CD19 CAR-T cell therapy have remained in drug-free remission for up to five years without ongoing immunosuppression. In this episode, we discuss how these findings are shifting the conversation from disease control to the possibility of cure, and what they could mean for lupus, inflammatory myopathies, systemic sclerosis, vasculitis, rheumatoid arthritis, and autoimmune diseases more broadly. We also explore CAR-T therapy, immune resets, regulatory T cells, relapse risk, and the future of rheumatology with Dr. Georg Schett. 

ESPN's way too early top 25 reaction! Way too early Big Ten tiermaker! All-Big Ten preseason watch list! The Sleepers Podcast is now available daily with new episodes every Monday-Friday! The College Basketball stock market is LIVE on Stakeholder! Buy low or sell high on teams as they lose and add players in the portal! Join using our link for an instant $15 bonus: https://stak3holder.com/join/sleepersmedia Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

6-2 Adam and Jordana 11a hour

Guest: Dr. Samuel Nobs is an Assistant Professor and Group Leader at the Institute for Research in Biomedicine in Switzerland. He discusses how microbes in the lungs and gut may shape respiratory immunity and influence susceptibility to infections and chronic lung diseases. He highlights his lab's work to uncover the mechanisms behind these interactions using microbiome analysis and advanced experimental models. Featured Products and Resources: Download a practical guide on everything you need to know about cell isolation techniques. Download a free wallchart on the production of CAR T cells. The Immunology Science Round Up Rabbit Immunity Evolves – Wild rabbits rapidly evolved resistance to myxoma virus through changes in highly diverse MHC immune genes. Antifungal Receptors Improve Vaccines – Targeting antifungal immune receptors with a mannan-based adjuvant boosts the strength, durability, and variant coverage of mRNA vaccine responses. Mapping Tumor Macrophage Diversity – Scientists have revealed how diverse tumor-associated macrophage subtypes promote tumor growth, immune suppression, and metastasis through interactions within the tumor microenvironment. Dietary Soy Shapes Immunity – Dietary soy shapes the gut microbiome to boost IgA-mediated immunity and enhance protection against intestinal infection in early life. Image courtesy of Dr. Samuel Nobs. Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

This month, the gals invite Cam Collins from Old Gods of Appalachia on the show to discuss Waffle House teleportation, a bowel movement bust, accidental nudes, a zombie rabbit, and one hell of an Easter egg. Tune in now for May's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.